Collection of Samples From Patients With MDS
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/28/2019 |
| Start Date: | April 6, 2017 |
| End Date: | March 5, 2021 |
| Contact: | Rafael Bejar, MD |
| Email: | rabejar@ucsd.edu |
| Phone: | 858-822-5485 |
Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens (MSA) for Use in Cellular Immunotherapy.
The purpose of this study is to collect information and bone marrow, blood, saliva, cheek
cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of
treating MDS.
cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of
treating MDS.
Goals of the study:
The purpose of this study is to collect the blood and marrow samples, and non-involved
fibroblasts, that are required to identify the unique, personalized array of mutation-driven
neoantigens that are expressed by the subject's MDS cells and to assess the feasibility of
immunizing and expanding one or more of the patient's T cells ex vivo for investigation of
their use as adoptive cellular immunotherapy.
The purpose of this study is to collect the blood and marrow samples, and non-involved
fibroblasts, that are required to identify the unique, personalized array of mutation-driven
neoantigens that are expressed by the subject's MDS cells and to assess the feasibility of
immunizing and expanding one or more of the patient's T cells ex vivo for investigation of
their use as adoptive cellular immunotherapy.
Patients must meet the following initial inclusion criteria:
- Diagnosis or suspected diagnosis of MDS or CCUS
- Age 18 or older
Patient exclusion criteria:
- Currently receiving or within 3 months has received hypomethylating agent(s),
lenalidomide, cytotoxic agents, or within the previous 4 weeks corticosteroids > 5 mg
prednisone daily or any other immunosuppressants
- Previous allogenic transplant
- Inability to provide consent
- Prisoners
We found this trial at
2
sites
9500 Gilman Dr
La Jolla, California 92093
La Jolla, California 92093
(858) 534-2230
Principal Investigator: Rafael Bejar, M.D., Ph.D.
Phone: 858-534-8127
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
Click here to add this to my saved trials
Irvine, California 92697
949-824-5011
Principal Investigator: Deepa Jeyakumar, M.D.
Phone: 877-827-8839
University of California, Irvine Since 1965, the University of California, Irvine has combined the strengths...
Click here to add this to my saved trials